Skip to Content
Biotechnology and health

Brain waves can tell us how much pain someone is in

The research could open doors for personalized brain therapies to target and treat the worst kinds of chronic pain.

scan of a patient with sensors embedded in head (highlighted in red) and wires connecting down to two receivers on chest
Prasad Shirvalkar

Brain signals can be used to detect how much pain a person is experiencing, which could overhaul how we treat certain chronic pain conditions, a new study has suggested.

The research, published in Nature Neuroscience today, is the first time a human’s chronic-pain-related brain signals have been recorded. It could aid the development of personalized therapies for the most severe forms of pain.

Chronic pain, defined as pain that lasts for three months or more, affects up to one in five people in the US—more than diabetes, high blood pressure, or depression. It can sometimes affect people after a stroke or limb amputation. Because we still don’t really understand how it affects the brain, it’s also very difficult to treat. Quality of life can be severely affected.

Researchers from the University of California, San Francisco, implanted electrodes in the brains of four people with chronic pain. The patients then answered surveys about the severity of their pain multiple times a day over a period of three to six months. After they finished filling out each survey, they sat quietly for 30 seconds so the electrodes could record their brain activity. This helped the researchers identify biomarkers of chronic pain in the brain signal patterns, which were as unique to the individual as a fingerprint.

Next, the researchers used machine learning to model the results of the surveys. They found they could successfully predict how the patients would score the severity of their pain by examining their brain activity, says Prasad Shirvalkar, one of the study’s authors. 

“The hope is that now that we know where these signals live, and now that we know what type of signals to look for, we could actually try to track them noninvasively,” he says. “As we recruit more patients, or better characterize how these signals vary between people, maybe we can use it for diagnosis.” 

The researchers also found they were able to distinguish a patient’s chronic pain from acute pain deliberately inflicted using a thermal probe. The chronic-pain signals came from a different part of the brain, suggesting that it’s not just a prolonged version of acute pain, but something else entirely.

Because different people experience pain in different ways, there is no one-size-fits-all approach to tackling it, which has proved a major challenge in the past. The team hopes that mapping individuals’ biomarkers will make it possible to better target therapeutic use of electrical brain stimulation, a treatment Shirvalkar likens to turning pain on or off like a thermostat.

The findings could be a big leap in pain treatment and could be especially helpful in treating people with chronic pain who have difficulty communicating, says Ben Seymour, a professor of clinical neuroscience at the University of Oxford, who was not involved in the project.

“This opens a new door to smart pain technologies, so I think this is a really important engineering hurdle that is now crossed,” he says. 

It also demonstrates the intensely personal ways in which people feel pain, and the importance to tailoring treatments to each person, adds Shirvalkar

“It’s clear that pain is so complex—and that individual people are so complex—that the only way to actually hear them and see them is to let them tell their side of the story,” he says.

Deep Dive

Biotechnology and health

FDA advisors just said no to the use of MDMA as a therapy

The studies demonstrating MDMA’s efficacy against PTSD left experts with too many questions to greenlight the treatment.

Biotech companies are trying to make milk without cows

The bird flu crisis on dairy farms could boost interest in milk protein manufactured in microorganisms and plants. 

What’s next for MDMA

The FDA is poised to approve the notorious party drug as a therapy. Here’s what it means, and where similar drugs stand in the US. 

My biotech plants are dead

Two ‘Firefly petunias’ perished in a shipping misadventure, but other customers have had better luck.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.